YUPELRI® (revefenacin) net sales of $66.3 million, recognized by Viatris, increased 22% year-over-year1 Pivotal Phase 3 CYPRESS study enrollment on track to complete by late summer Completed sale of TRELEGY ELLIPTA royalty interest to GSK for $225 million TRELEGY year-to-date sales on...
Related Questions
What are the tax implications of the TRELEGY royalty sale on the company's net income?
What is the impact of the $225 million TRELEGY royalty interest sale on TVTK's cash position and balance sheet leverage?
How did the reported net sales of YUPELRI® compare to analysts' expectations for the quarter?
Did the company provide EPS guidance for the full year, and how does it compare to consensus estimates?
What are the projected revenues from the CYPRESS Phase 3 study, and when are results expected?
How does the 22% YoY growth in YUPELRI® sales compare to growth rates of competing COPD/respiratory products?
What are the terms of the TRELEGY royalty sale—any earn‑out provisions or future royalty obligations?
Will the $225 million proceeds be allocated to R&D, debt reduction, or share repurchases?
How does the current operating margin compare to prior quarters and to peer companies?
How might the sale of the TRELEGY royalty interest affect the company’s valuation multiples (P/E, EV/EBITDA) going forward?
What is the expected timeline and market potential for the CYPRESS study results to affect future revenue?
What is the outlook for the remaining pipeline assets beyond CYPRESS—any upcoming INDs or trials?